Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100737 · ClinicalTrials.gov registry record · Phase 2
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
A Phase 2 study, sponsored by Chiron Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT00100737: Clinical Trial Phase 2 study, sponsored by Chiron Corporation.
NCT00100737 is a Phase 2 study that was terminated before completion, run by Chiron Corporation. The registered enrollment target is 300 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00100737, a Phase 2 study, was terminated before completion, sponsored by Chiron Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL subjects that have never received rituximab as a treatment and are refractory or relapsed after previous chemotherapy.
Interventions
- DRUG rituximab
- DRUG interleukin-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Phase | Phase 2 |
Why NCT00100737 stopped before completion
NCT00100737 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher).
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT00100737 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00100737 about?
NCT00100737 is a clinical study titled "Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)". The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL subjects that have never received rituximab as a treatment and are refractory...
What is the current status of trial NCT00100737?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 300 participants.
What interventions are being tested in trial NCT00100737?
The interventions under investigation include: rituximab (DRUG), interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT00100737?
This trial is sponsored by Chiron Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00100737's enrollment target sits among peer trials
300 167th of 2000 higher than 1,813 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics